Yvonne McGrath
CIK 1816213 · Chief Scientific Officer · last filed 2025-08-29
Yvonne McGrath is a Chief Scientific Officer who has filed 13 SEC Form 4 insider transactions across 1 company since 2021. The most recent filing, for ITOS, was dated Aug 29, 2025. Across all open-market trades the lifetime net is −$1.2M, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
1
13
-$1.23M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| iTeos Therapeutics, Inc. (ITOS) Delisted | Chief Scientific Officer | 0 | $10.15 | $0 | -$1.23M | 13 | 2025-08-29 |
Recent Filings
13 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-08-29 | iTeos Therapeutics, Inc. (ITOS) Delisted | Mixed | −46,300 | $0 | EDGAR |
| 2025-03-11 | iTeos Therapeutics, Inc. (ITOS) Delisted | Grant (A) | +15,300 | $0 | EDGAR |
| 2024-03-08 | iTeos Therapeutics, Inc. (ITOS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-12-07 | iTeos Therapeutics, Inc. (ITOS) Delisted | Grant (A) | +31,000 | $0 | EDGAR |
| 2023-03-10 | iTeos Therapeutics, Inc. (ITOS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-03-14 | iTeos Therapeutics, Inc. (ITOS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-03-02 | iTeos Therapeutics, Inc. (ITOS) Delisted | Mixed | — | -$325.2K | EDGAR |
| 2021-06-10 | iTeos Therapeutics, Inc. (ITOS) Delisted | Mixed | — | -$125.0K | EDGAR |
| 2021-06-03 | iTeos Therapeutics, Inc. (ITOS) Delisted | Mixed | — | -$126.4K | EDGAR |
| 2021-06-03 | iTeos Therapeutics, Inc. (ITOS) Delisted | Mixed | — | -$140.3K | EDGAR |